cas 2304513-76-4|| where to buy 3-(6-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Nom du produit:3-(6-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione

IUPAC Name:3-(6-bromo-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione

: CAS：2304513-76-4; Formule moléculaire：C13H11BrN2O3; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)
CM621861-5g	in stock	ǠƐȅ
CM621861-25g	in stock	ƴǠœ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2304513-76-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2304513-76-4; Formule moléculaire:C13H11BrN2O3; Point de fusion:-; Code SMILES:BrC1=CC2=C(CN(C3CCC(=O)NC3=O)C2=O)C=C1; Densité:

: Numéro de catalogue:CM621861; Poids moléculaire:323.15; Point d'ébullition:; N° Mdl:; Stockage:

: Piperidines; Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.; Piperidine,Piperidine Price; if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

: MRT-2359; Aberrant MYC pathway activation is found in cancer cells, while MYC-induced protein translation depends on GSPT1. Molecular glues targeting GSPT1 is identified as a potential treatment method in oncology. Monte Rosa’s MRT-2359 is an oral and selective molecular glue degrader of the translation termination factor GSPT1. The targeted GSPT1 degradation results in disrupting MYC-driven protein translation and reducing MYC-oncogenic signaling.
MRT-2359 is in an ongoing phase 1/2 study in MYC-driven solid tumors with a current assessment of 0.75 mg dose level. The final phase 2 dose determination and updated clinical results are anticipated in the second half of 2024. MRT-2359 previously received Fast Track Designation in patients with previously treated, metastatic NSCLC with L-MYC or N-MYC expression, Orphan Drug Designation in small cell lung cancer (SCLC), and Fast Track Designation in previously treated, metastatic SCLC with L-MYC or N-MYC expression.